Doxepin (Silenor) 3mg is a prescription sleep medication used to help manage insomnia, particularly difficulty staying asleep throughout the night. Each pack contains 30 tablets.
Format30 Tablets
Concentration3mg
Package Selected: 5 Pack Special
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
Silenor contains doxepin hydrochloride, a medication used at low doses for the treatment of insomnia characterized by difficulty maintaining sleep. Although doxepin belongs pharmacologically to the tricyclic antidepressant family, the 3mg Silenor formulation is specifically designed for sleep maintenance insomnia rather than antidepressant treatment.
At low doses, doxepin’s sleep promoting effects are believed to occur primarily through antagonism of histamine H1 receptors in the central nervous system. Doxepin has a high affinity for these receptors, reducing histamine mediated wakefulness and helping support more continuous sleep during the night.
This mechanism differs from many traditional sedative hypnotic medications. Rather than acting primarily through GABA receptors, low dose doxepin targets the histamine system involved in maintaining wakefulness, making it particularly useful for patients whose main insomnia symptom is waking repeatedly or having difficulty remaining asleep.
Silenor is available in 3mg and 6mg tablet strengths. Health Canada lists Silenor 3mg as a marketed prescription medication containing doxepin hydrochloride, calculated as 3mg doxepin per tablet.
This product provides:
Active Ingredient: Doxepin
Form: Doxepin Hydrochloride
Strength: 3mg per tablet
Quantity: 30 Tablets
Drug Class: Tricyclic Compound / H1 Histamine Receptor Antagonist at low dose
Primary Indication: Sleep Maintenance Insomnia
The 3mg strength is an established Silenor dose and is also the recommended initial dose listed for elderly patients, while some other adults may also be prescribed 3mg when clinically appropriate. Treatment should be individualized by a healthcare professional.
Common adverse effects associated with low dose Silenor include sleepiness or sedation, nausea, and upper respiratory tract symptoms. Because doxepin can impair alertness and coordination, patients should be aware of possible next day impairment and should avoid hazardous activities if they remain drowsy.
Alcohol and other central nervous system depressants can increase the sedating effects of doxepin and should not be combined without appropriate medical guidance. Silenor is also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), those who have recently used an MAOI, and individuals with untreated narrow angle glaucoma or severe urinary retention.
Doxepin 3mg is a prescription medication and should be used according to the directions of a qualified healthcare professional.
SILENOR is a prescription low-dose doxepin medication used for insomnia. Each tablet contains doxepin hydrochloride equivalent to 3mg of doxepin, with 30 tablets supplied per package. At this low dose, its sleep promoting activity is primarily associated with blockade of histamine H1 receptors.
SILENOR is medically indicated for the treatment of insomnia characterized by difficulty staying asleep. It is particularly used for sleep maintenance insomnia rather than being positioned as a general sedative or as an antidepressant at the 3mg strength.
At the low doses used in SILENOR, doxepin primarily blocks histamine H1 receptors in the central nervous system. Histamine is an important wake promoting neurotransmitter, so reducing H1 receptor signaling can help decrease nighttime wakefulness and improve sleep maintenance.
Doxepin has an apparent terminal elimination half-life of approximately 15.3 hours. Its active metabolite, nordoxepin, has a longer half-life of approximately 31 hours. Individual clearance can vary based on factors such as age, liver function, and medications that affect CYP2C19 or CYP2D6 metabolism.
SILENOR can cause sedation and next day impairment, and its effects may be increased by alcohol or other central nervous system depressants. It should not be used with monoamine oxidase inhibitors and is contraindicated in patients with untreated narrow angle glaucoma or severe urinary retention. Patients should use it only when they can obtain an adequate period of sleep and under appropriate medical supervision.
